NEW APPROACHES TO TREATMENT OF AGE-RELATED MACULAR DEGENERATION
Authors: Soboleva Iryna Anatoliivna 
Published: March 2020

Age−related macular degeneration is a leading cause of central vision loss in people over 50 years of age. The rising incidence and significant risk of disability of the working population make this pathology a serious medical and social problem. With an early diagnosis of this condition and timely treatment, it is possible to avoid a loss of visual functions, to achieve a long−term remission or its reverse development. But there is no specific treatment for this disease. One of the drugs, affecting the functional state of retina in the patients with macular dystrophy is the "Visiloton Complex". To show its efficiency, a study was conducted in which 70 patients (70 eyes) with age−related macular degeneration of "dry form" participated. All the patients underwent a complete ophthalmic examination: visometry, biomicroscopy, computer static perimetry (Humphrey). The eye retinas were investigated using optical coherence tomography. The results of the study showed the feasibility of using "Visiloton Complex", as evidenced by a significant increase in visual functions in 65 % of patients. Under the influence of the drug the performance of the central and peripheral vision was improved, which was due to its strong antioxidant and vasoconstrictive action. Optical coherence tomography data confirm the positive effect of "Visiloton Complex" on neuroepithelial cells, as indicated by a decrease in retinal thickness under the drug influence. The use of "Visiloton Complex", comprising vitamins and minerals that normalize metabolism, possessing antioxidant action, protect the body against the effect of adverse environmental factors, contributes to an improvement of general state and well−being of patients with age−related macular degeneration.

Key words: macular degeneration, visual acuity, "Visiloton Complex" drug.Age−related macular degeneration is a leading cause of central vision loss in people over 50 years of age. The rising incidence and significant risk of disability of the working population make this pathology a serious medical and social problem. With an early diagnosis of this condition and timely treatment, it is possible to avoid a loss of visual functions, to achieve a long−term remission or its reverse development. But there is no specific treatment for this disease. One of the drugs, affecting the functional state of retina in the patients with macular dystrophy is the "Visiloton Complex". To show its efficiency, a study was conducted in which 70 patients (70 eyes) with age−related macular degeneration of "dry form" participated. All the patients underwent a complete ophthalmic examination: visometry, biomicroscopy, computer static perimetry (Humphrey). The eye retinas were investigated using optical coherence tomography. The results of the study showed the feasibility of using "Visiloton Complex", as evidenced by a significant increase in visual functions in 65 % of patients. Under the influence of the drug the performance of the central and peripheral vision was improved, which was due to its strong antioxidant and vasoconstrictive action. Optical coherence tomography data confirm the positive effect of "Visiloton Complex" on neuroepithelial cells, as indicated by a decrease in retinal thickness under the drug influence. The use of "Visiloton Complex", comprising vitamins and minerals that normalize metabolism, possessing antioxidant action, protect the body against the effect of adverse environmental factors, contributes to an improvement of general state and well−being of patients with age−related macular degeneration.

Key words: macular degeneration, visual acuity, "Visiloton Complex" drug.